PBI Schedule 13D: Hestia’s 12.1M-Share Stake, New Director Named
Rhea-AI Filing Summary
Hestia Capital Management and related entities have filed Amendment No. 10 to their Schedule 13D on Pitney Bowes Inc. (PBI). The filing, dated 16 June 2025, discloses updated ownership levels and a governance development stemming from the January 31, 2024 cooperation agreement between the parties.
Ownership detail
- Hestia Capital Partners LP directly owns 4,810,917 shares (≈2.7% of the 181,253,371 shares outstanding as of 30 April 2025).
- Helios I, LP directly owns 6,639,492 shares (≈3.7%).
- Separately managed accounts (SMAs) advised by Hestia hold 584,636 shares.
- Collectively, Hestia Capital Partners GP, LLC may be deemed to beneficially own 11,450,409 shares (≈6.3%).
- Hestia Capital Management, LLC and Kurtis J. Wolf (CEO of PBI and Hestia’s Managing Partner) report aggregate beneficial ownership of 12,070,325 shares, equating to ≈6.7% of the outstanding common stock.
All shares were purchased in open-market transactions with working capital; cumulative purchase prices total approximately $42.5 million for Hestia Capital and Helios combined, plus about $2.3 million for the SMAs. Mr. Wolf’s personal 35,280 shares were acquired through director compensation arrangements.
Governance update
On 17 June 2025, Pitney Bowes announced that the Board appointed Brent Rosenthal as a director effective 16 June 2025. His appointment is made under Section 1(c) of the January 2024 Cooperation Agreement and he replaces Lance Rosenzweig as a “Replacement Director” for purposes of that agreement.
Key takeaways for investors
- Hestia’s group remains the largest reported active shareholder, controlling nearly 7 % of PBI, reinforcing ongoing activist oversight.
- The Rosenthal appointment signals continued implementation of the cooperation agreement and may influence strategic direction and capital allocation at PBI.
Positive
- Activist involvement reinforced: Appointment of Brent Rosenthal maintains Hestia’s representation on Pitney Bowes’ board, supporting continued governance oversight.
- Substantial ownership: Hestia group retains a significant 6.7 % stake, aligning interests with other shareholders.
Negative
- None.
Insights
TL;DR: Hestia keeps ≈7 % stake; new board appointee under cooperation pact, sustaining activist pressure on Pitney Bowes.
Hestia’s latest Schedule 13D amendment confirms its sizeable, stable stake (≈12.1 million shares) and highlights the seating of Brent Rosenthal, replacing Rosenzweig, in line with January 2024 terms. The group’s purchase cost basis (~$43 million) suggests an average entry price well below PBI’s historical highs, indicating financial headroom to push for value-enhancing measures. From a governance standpoint, continuity of the agreement keeps three Hestia-aligned directors on the board, maintaining leverage over operational turnaround initiatives. While no incremental share purchases are disclosed, the filing reassures investors that activist engagement remains intact. Overall, the disclosure is modestly positive, signalling steady strategic oversight without introducing material new risk.